<?xml version="1.0" encoding="UTF-8"?><OAI-PMH
	xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2019-03-02T19:34:20Z</responseDate><request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:2696133" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request><GetRecord><record><header><identifier>oai:pubmedcentral.nih.gov:2696133</identifier><datestamp>2009-07-28</datestamp><setSpec>nihpa</setSpec><setSpec>pmc-open</setSpec><setSpec>manuscript</setSpec></header><metadata><article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.0/ https://jats.nlm.nih.gov/archiving/1.0/xsd/JATS-archivearticle1.xsd" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-journal-id">0410462</journal-id>
      <journal-id journal-id-type="pubmed-jr-id">6011</journal-id>
      <journal-id journal-id-type="nlm-ta">Nature</journal-id>
      <journal-id journal-id-type="iso-abbrev">Nature</journal-id>
      <journal-title-group>
        <journal-title>Nature</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0028-0836</issn>
      <issn pub-type="epub">1476-4687</issn>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="accession">PMC2696133</article-id>
      <article-id pub-id-type="pmcid">PMC2696133</article-id>
      <article-id pub-id-type="pmc-uid">2696133</article-id>
      <article-id pub-id-type="pmid">19078957</article-id>
      <article-id pub-id-type="pmid">19078957</article-id>
      <article-id pub-id-type="doi">10.1038/nature07586</article-id>
      <article-id pub-id-type="manuscript">nihpa74666</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Frequent somatic mutations of <italic>GNAQ</italic> in uveal melanoma and blue nevi</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Van Raamsdonk</surname>
            <given-names>Catherine D.</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Bezrookove</surname>
            <given-names>Vladimir</given-names>
          </name>
          <xref ref-type="aff" rid="A2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Green</surname>
            <given-names>Gary</given-names>
          </name>
          <xref ref-type="aff" rid="A2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Bauer</surname>
            <given-names>JÃ¼rgen</given-names>
          </name>
          <xref ref-type="aff" rid="A2">2</xref>
          <xref ref-type="aff" rid="A3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Gaugler</surname>
            <given-names>Lona</given-names>
          </name>
          <xref ref-type="aff" rid="A2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>OâBrien</surname>
            <given-names>Joan M.</given-names>
          </name>
          <xref ref-type="aff" rid="A4">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Simpson</surname>
            <given-names>Elizabeth M.</given-names>
          </name>
          <xref ref-type="aff" rid="A5">5</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Barsh</surname>
            <given-names>Gregory S.</given-names>
          </name>
          <xref ref-type="aff" rid="A6">6</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Bastian</surname>
            <given-names>Boris C.</given-names>
          </name>
          <xref ref-type="aff" rid="A2">2</xref>
          <xref ref-type="corresp" rid="CR1">7</xref>
        </contrib>
      </contrib-group>
      <aff id="A1"><label>1</label>
Department of Medical Genetics, University of British Columbia, Vancouver BC
</aff>
      <aff id="A2"><label>2</label>
Department of Dermatology and Comprehensive Cancer Center, University of California, San Francisco
</aff>
      <aff id="A3"><label>3</label>
Department of Dermatology, University of TÃ¼bingen, Germany
</aff>
      <aff id="A4"><label>4</label>
Department of Ophthalmology and Comprehensive Cancer Center, University of California, San Francisco
</aff>
      <aff id="A5"><label>5</label>
Centre for Molecular Medicine and Therapeutics and Department of Medical Genetics, University of British Columbia, Vancouver BC
</aff>
      <aff id="A6"><label>6</label>
Department of Genetics, Stanford University, Stanford CA
</aff>
      <author-notes>
        <corresp id="CR1"><label>7</label>
To whom correspondence should be addressed
</corresp>
      </author-notes>
      <pub-date pub-type="nihms-submitted">
        <day>5</day>
        <month>5</month>
        <year>2009</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>10</day>
        <month>12</month>
        <year>2008</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <day>29</day>
        <month>1</month>
        <year>2009</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>28</day>
        <month>7</month>
        <year>2009</year>
      </pub-date>
      <volume>457</volume>
      <issue>7229</issue>
      <fpage>599</fpage>
      <lpage>602</lpage>
      <!--elocation-id from pubmed: 10.1038/nature07586-->
      <permissions>
        <license xlink:href="http://www.nature.com/authors/editorial_policies/license.html#terms">
          <license-p>Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:<ext-link ext-link-type="uri" xlink:href="http://www.nature.com/authors/editorial_policies/license.html#terms">http://www.nature.com/authors/editorial_policies/license.html#terms</ext-link></license-p>
        </license>
      </permissions>
      <abstract>
        <p id="P1"><italic>BRAF</italic> and <italic>NRAS</italic> are common targets for somatic mutations in benign and malignant neoplasms that arise from melanocytes situated in epithelial structures and lead to constitutive activation of the MAP-kinase pathway<xref rid="R1" ref-type="bibr">1</xref>, <xref rid="R2" ref-type="bibr">2</xref>. However, <italic>BRAF</italic> and <italic>NRAS</italic> mutations are absent in a number of other melanocytic neoplasms in which the equivalent oncogenic events are currently unknown<xref rid="R3" ref-type="bibr">3</xref>. We report frequent somatic mutations in the heterotrimeric G protein alpha subunit, <italic>GNAQ</italic>, in blue nevi (83%) and ocular melanoma of the uvea (46%). The mutations occur exclusively in codon 209 in the ras-like domain and result in constitutive activation, turning <italic>GNAQ</italic> into a dominant acting oncogene. Our results demonstrate an alternative route to MAP-kinase activation in melanocytic neoplasia providing new opportunities for therapeutic intervention.</p>
      </abstract>
    </article-meta>
  </front>
  <body>
    <p id="P2">Most melanocytic neoplasms, benign melanocytic nevi as well as melanomas, originate from melanocytes situated within epithelial structures throughout the body, mostly the sun-exposed skin of individuals with light complexion. The majority of nevi and melanomas show oncogenic mutations in signaling components of the MAP kinase pathway, in particular <italic>BRAF</italic> and <italic>NRAS</italic><xref rid="R1" ref-type="bibr">1</xref>,<xref rid="R2" ref-type="bibr">2</xref>. However, a subset of melanocytic neoplasms does not show mutations in <italic>BRAF</italic> and <italic>NRAS</italic><xref rid="R3" ref-type="bibr">3</xref>. One category, uveal melanoma, arises from melanocytes within the choroidal plexus of the eye and is biologically distinct from cutaneous melanoma by characteristic cytogenetic alterations<xref rid="R4" ref-type="bibr">4</xref> and a very strong propensity to metastasize to the liver<xref rid="R5" ref-type="bibr">5</xref>. The other category are intradermal melanocytic proliferations, which can be congenital or acquired, and present in diverse ways ranging from discrete bluish moles (blue nevi) to large blue-gray patches affecting the conjunctiva and periorbital skin (nevus of Ota), shoulders (nevus of Ito), and the lower back (Mongolian spot)<xref rid="R6" ref-type="bibr">6</xref>. A potential connection between intradermal melanocytic neoplasms and uveal melanoma is suggested by the fact that nevus of Ota is a risk factor for uveal melanoma and by an overlap in some of the histomorphologic features of the two conditions<xref rid="R7" ref-type="bibr">7</xref>.</p>
    <p id="P3">Using a forward genetic screen in mice we previously identified hypermorphic mutations in <italic>GNAQ</italic> or <italic>GNA11</italic>as a cause of diffuse skin hyperpigmentation that was due to an increase of intradermal, but not epidermal, melanocytes<xref rid="R8" ref-type="bibr">8</xref>. <italic>GNAQ</italic> and <italic>GNA11</italic> encode members of the q class of G-protein alpha subunits involved in mediating signals between G-protein coupled receptors (GPCRs) and downstream effectors. To investigate whether similar pathways were involved in humans, we sequenced the entire coding regions of <italic>GNAQ</italic> and <italic>GNA11</italic> in a broad spectrum of benign and malignant melanocytic neoplasms. We found mutations in <italic>GNAQ</italic> in 83% of blue nevi (n=29), 50% of âmalignant blue neviâ (n=2), and 46% of uveal melanomas (n=48) (<xref ref-type="table" rid="T1">Table 1</xref>, <xref ref-type="supplementary-material" rid="SD1">Supplementary Information, Figure 1a</xref>). Nevus of Ota is a condition in which a subtle proliferation of intradermal melanocytes results in hyperpigmentation of the conjunctiva and periorbital skin. To increase the detection limit for mutations in a background of normal cells, we used a mutation-specific assay and found a mutation in one of 14 cases (6%) (<xref ref-type="supplementary-material" rid="SD1">Supplementary Information, Figure 1b</xref>). No somatic point mutations were found in <italic>GNA11</italic>.</p>
    <p id="P4">All mutations in <italic>GNAQ</italic> were somatically acquired as assessed by sequencing DNA from adjacent tissue, and occurred exclusively at codon 209 (<xref ref-type="supplementary-material" rid="SD1">Supplementary Information, Table 1</xref>). The glutamine at codon 209 lies within the <italic>ras</italic>-like domain of <italic>GNAQ</italic> (corresponding to residue 61 of RAS and is essential for GTP hydrolysis <xref rid="R9" ref-type="bibr">9</xref>. In RAS family members, mutations at this site, and at codon 12, cause loss of GTPase activity with constitutive activation<xref rid="R9" ref-type="bibr">9</xref>-<xref rid="R11" ref-type="bibr">11</xref>. There is no equivalent of codon 12 in <italic>GNAQ</italic>. In contrast to the findings in humans, the mutations found in the dark skinned mice occurred at I63, V179, and F335 in the mouse proteins and do not cause constitutive activation<xref rid="R8" ref-type="bibr">8</xref>.</p>
    <p id="P5">To date no mutations of <italic>GNAQ</italic> have been described in human neoplasia, but <italic>GNAQ<sup>Q209L</sup></italic> has been demonstrated to transform 3T3 cells<xref rid="R11" ref-type="bibr">11</xref>. In addition, mutations of the corresponding codon in G alpha S (<italic>GNAS</italic>) are found in human pituitary and thyroid tumors<xref rid="R10" ref-type="bibr">10</xref>, <xref rid="R12" ref-type="bibr">12</xref>. To assess the effect of <italic>GNAQ<sup>Q209L</sup></italic> on human melanocytes, we established epitope-tagged lentiviral expression constructs to transfect normal and genetically modified human melanocytes, the latter of which have an extended life span, but still require additional factors (cAMP, TPA) for growth (hTERT/CDK4<sup>R24C</sup>/p53<sup>DD</sup> melanocytes<xref rid="R13" ref-type="bibr">13</xref>). Stable transfection of <italic>GNAQ<sup>Q209L</sup></italic> into primary human melanocytes was insufficient to induce anchorage independent growth (data not shown). In contrast, transfection of <italic>GNAQ<sup>Q209L</sup></italic> into hTERT/CDK4<sup>R24C</sup>/p53<sup>DD</sup> melanocytes resulted in anchorage independent growth with efficiencies comparable or slightly greater than transfection with NRAS<sup>Q61R</sup> (<xref ref-type="fig" rid="F1">Figure 1a</xref>, <xref ref-type="supplementary-material" rid="SD1">Supplementary Information, Table 2</xref>). Furthermore, GNAQ<sup>Q209L</sup> but not GNAQ<sup>wt</sup> induced abnormally enlarged nuclei with markedly irregular contours (<xref ref-type="fig" rid="F1">Figure 1b</xref>, <xref ref-type="supplementary-material" rid="SD1">Supplementary Information, Table 3</xref>). To validate <italic>GNAQ<sup>Q209L</sup></italic> as an oncogene in vivo, we performed tumorigenicity studies in nude mice (<xref ref-type="fig" rid="F1">Figure 1c</xref>). <italic>GNAQ<sup>Q209L</sup></italic>, but not GNAQ<sup>wt</sup> or vector control transfected melanocytes gave rise to heavily pigmented tumors at the injection site. The tumor morphology resembled closely the spectrum of atypical blue nevus that in humans has been termed animal type melanoma or pigmented epithelioid melanocytoma<xref rid="R6" ref-type="bibr">6</xref>.</p>
    <p id="P6">Signaling pathways downstream of GNAQ include activation of protein kinase C family members via the release of diacylglycerol (DAG) by phospholipase CÎ². Consistently, <italic>GNAQ<sup>Q209L</sup></italic>-transformed melanocytes grew in soft agar in the absence of TPA, a synthetic DAG analog (<xref ref-type="fig" rid="F1">Figure 1a</xref>, <xref ref-type="supplementary-material" rid="SD1">Supplementary Information, Table 2</xref>). PKC activation by way of GNAQ activation can activate the MAP-kinase pathway in other cell types<xref rid="R14" ref-type="bibr">14</xref>. Uveal melanomas display MAP-kinase activation<xref rid="R15" ref-type="bibr">15</xref>, but none of the uveal melanomas we examined in our study showed mutations in BRAF or NRAS (<xref ref-type="supplementary-material" rid="SD1">Supplementary Information, Table 4</xref>), consistent with other studies<xref rid="R3" ref-type="bibr">3</xref>. We therefore tested whether <italic>GNAQ<sup>Q209L</sup></italic> would contribute to MAP-kinase pathway activation in human melanocytes and uveal melanoma cells. As shown in <xref ref-type="fig" rid="F2">Figure 2</xref>, GNAQ<sup>Q209L</sup> transfection into hTERT/CDK4<sup>R24C</sup>/p53<sup>DD</sup> melanocytes caused increased levels of phospho-ERK compared to control cells transfected with wildtype <italic>GNAQ</italic> (<italic>GNAQ<sup>WT</sup></italic>) or an empty vector (Vector). Similar results were obtained with <italic>GNAQ<sup>Q209L</sup></italic> transfection into primary human melanocytes and 293T cells (see <xref ref-type="supplementary-material" rid="SD1">Supplementary Information, Figure 2</xref>). Conversely, siRNA-mediated knock-down of GNAQ in the uveal melanoma cell line, OMM1.3, which harbors the <italic>GNAQ</italic>-<sup>Q209L</sup> mutation, resulted in a decrease of phospho-ERK levels (<xref ref-type="fig" rid="F3">Figure 3a</xref>). In addition, GNAQ knock-down in OMM1.3 cells causes a substantial decrease in cell number (<xref ref-type="fig" rid="F3">Figure 3b</xref>), loss of anchorage independent growth (<xref ref-type="fig" rid="F3">Figure 3c</xref>) and a marked increase in sub-G0/G1 population (<xref ref-type="fig" rid="F3">Figure 3d</xref>) as compared to control cells. Similar results were obtained when another uveal melanoma cell line Mel202 was treated with siRNA against <italic>GNAQ<sup>Q209L</sup></italic> (<xref ref-type="supplementary-material" rid="SD1">Supplementary Information, Figure 3</xref>). Mel202 and OMM1.3 stem from different patients, as confirmed by DNA fingerprinting (data not shown.)</p>
    <p id="P7">In summary, our data identify <italic>GNAQ</italic> as a novel oncogene in human neoplasia. GNAQ operates downstream of several GPCRs that are important in melanocyte homeostasis and neoplasia. GNAQ is involved in endothelin signaling, which is essential for melanocyte survival early during development<xref rid="R16" ref-type="bibr">16</xref>. Gq signaling may also contribute to the association observed for melanoma invasion and metastasis with Wnt family members<xref rid="R17" ref-type="bibr">17</xref>, since Frizzled receptors can couple to Gq<xref rid="R18" ref-type="bibr">18</xref>. Furthermore, Gq signaling is likely to underlie the ability of the metabotropic glutamate receptor gene, <italic>GRM1</italic>, to cause dermal melanocytic neoplasia and ocular melanoma in transgenic mice<xref rid="R19" ref-type="bibr">19</xref>.</p>
    <p id="P8">The location of neoplastic melanocytes induced by somatic <italic>GNAQ</italic> mutation in humans is very similar to the location of melanocytes affected by germline <italic>GNAQ</italic> (and <italic>GNA11</italic>) mutations in mice<xref rid="R8" ref-type="bibr">8</xref>. In both cases, the melanocytic proliferations spare epithelial structures. However, our previous work in mice suggests that these mutations do not interfere with homing of melanocytes to epithelial structures, but instead lead to an increase of the total melanoblast pool<xref rid="R8" ref-type="bibr">8</xref>. In humans, it is not known whether the adult dermis contains any residual sparse populations of melanocytes in which <italic>GNAQ</italic> mutations could occur and induce intradermal melanocytic tumors<xref rid="R6" ref-type="bibr">6</xref>, <xref rid="R20" ref-type="bibr">20</xref>. Acquired blue nevi are typically small and well circumscribed, raising the possibility that they arise from an intradermal population of melanocytes that remains to be characterized. By contrast, nevus of Ota involves different structures such as periorbital skin, conjunctiva, neurovascular bundles, ganglia, and uvea, suggesting these <italic>GNAQ</italic> mutations may arise early in a migrating melanoblast. This later neoplasm shows strong similarities to the murine studies and indicates a specific window for Gq signaling in terms of cell type and developmental time that is conserved across species.</p>
    <p id="P9">Our findings identify <italic>GNAQ</italic> as a genetic link between nevus of Ota and uveal melanoma and help explain why nevi of Ota are a risk factor for uveal melanoma<xref rid="R7" ref-type="bibr">7</xref>. The risk is small, as only about 1 in 400 nevi of Ota progress to uveal melanoma and future studies will have to elucidate the role of <italic>GNAQ</italic> mutations in this risk. In our experiments, <italic>GNAQ</italic> behaves similar to the oncogenes, <italic>BRAF</italic> and <italic>NRAS</italic>, in that its mutation is insufficient for full progression to melanoma. This is illustrated best by blue nevi, which are generally stable lesions that rarely become malignant (âmalignant blue nevusâ)<xref rid="R6" ref-type="bibr">6</xref>. Thus MAPK activation appears to be an early event in neoplasms with <italic>GNAQ</italic> mutations, as it is in neoplasms with <italic>BRAF</italic> and <italic>NRAS</italic> mutations<xref rid="R2" ref-type="bibr">2</xref>. Further studies are necessary to determine whether the difference in tissue involvement between melanocytic neoplasms with <italic>BRAF</italic> mutations and those with <italic>GNAQ</italic> mutations is a functional consequence of the mutations themselves, or indicates differences in the target cell populations in which these mutations occur.</p>
    <p id="P10">Uveal melanoma is a highly aggressive cancer without any effective treatment options once it metastasizes. Although it only accounts for approximately 5% of all melanomas, it represents the most common intraocular malignancy in the United States and has a five-year disease specific survival rate of approximately 70%<xref rid="R21" ref-type="bibr">21</xref>. Our study identifies signaling components downstream of <italic>GNAQ</italic> as potential targets in this dreadful disease.</p>
    <sec sec-type="methods" id="S1">
      <title>Methods Summary</title>
      <p id="P11">Detailed descriptions of reagents and experiments can be found in the full Methods. <italic>GNAQ</italic> and <italic>GNA11</italic> were sequenced in DNA extracted from archival, paraffin-embedded biopsies under the approval of the institutional review boards at UCSF, Stanford and UBC. Primary, hTERT/CDK4<sup>R24C</sup>/p53<sup>DD</sup>, and melan-a melanocytes were stably infected with FG12 lentiviral expression vectors expressing flag-tagged wildtype GNAQ or GNAQ<sup>Q209L</sup>, empty vector or NRAS<sup>Q61R</sup>. Infection efficiencies were estimated by the proportion of cells expressing GFP. To assess anchorage independent growth, melanocytes were plated on soft agar, cultured for 28 days and stained with 0.005% crystal violet. For tumorigenicity experiments, 1 million lentiviral transfected melan-a cells were injected into each nude mouse, housed at UBC according to CCAC guidelines. For immunofluorescence, lentiviral transfected cells were cultured on coverslips for 5 days and incubated with antibodies against pERK (E-4, Santa Cruz Biotechnology), cyclin D1 (M-20, Santa Cruz Biotechnology) and GNAQ (C-19, Santa Cruz biotechnology). OMM1.3 and Mel202 cells were transfected with two different pools of siRNA against GNAQ: pool 1: 5â²-CAAUAAGGCUCAUGCACAAUU-3â², 5â²-CGACGAGAAUAUCAAUUAUUU-3â², 5â²-GCAAGAGUACGUUUAUCAAUU-3â², 5â²-UAGUAGCGCUUAGUGAAUAUU-3â²; pool 2: 5â²-AUGCACAAUUAGUUCGAGAUU-3â², 5â²-UAUGAUAGACGACGAGAAUUU-3â², 5â²-CAGACAAUGAGAACCGAAUUU-3â², 5â²- CGCCACAGACACCGAGAAUUU-3â²). For western blot analysis, 5-20 Î¼g of protein was extracted from lentiviral or siRNA transfected cells. Primary antibodies were: pERK, cyclin D1, GNAQ, Cyclophilin B (Abcam), anti-FLAG M2 (Sigma), Anti-ERK Â½ pAb (Promega), and Î²-actin (Sigma). Secondary antibodies were labeled with horseradish peroxidase. Relative cell numbers were quantified by the CyQUANTÂ® Cell Proliferation Assay Kit (Invitrogen). Cell cycle measurements were performed on a FACSCalibur after staining with propidium iodide. Studentâs t-test and Fisherâs Exact test were used for statistical comparison.</p>
    </sec>
    <sec sec-type="methods" id="S2">
      <title>Full methods</title>
      <sec id="S3">
        <title>DNA</title>
        <p id="P12">DNA was obtained from archival paraffin-embedded biopsies under the approval of the institutional review boards at UCSF, Stanford and the University of British Columbia. For each sample, 20 um sections were microdissected, washed in xylene and ethanol and digested with proteinase K. DNA was then extracted with phenol-choloroform-isoamyl-alcohol.</p>
      </sec>
      <sec id="S4">
        <title>Sequencing</title>
        <p id="P13">Biopsy DNA was amplified using PCR. For <italic>GNAQ</italic> exon 5, the primers used were 5â²-cccacaccctactttctatcatttac-3â² and 5â²-ttttccctaagtttgtaagtagtgc-3â². PCR products were used as templates for sequencing reactions using Big Dye (ABI). Samples identified with mutations in both sequencing directions were replicated at least twice. Mutations 1-3 were verified with RFLP. Mutations 1 and 2 create an Eco0109I restriction site, while mutation 3 produces an AflII restriction site.</p>
      </sec>
      <sec id="S5">
        <title>Sensitive assay for Q209 mutations in mixed cell populations</title>
        <p id="P14">The peptide nucleic acid, Actctctgacctttggc-CONH<sub>2</sub>, was resuspended in 50% DMF and used at a final concentration of 4 uM against 2 ng template DNA in a 25 ul reaction. The reaction conditions were 0.25 mM dNTPs, 6X BSA, 2 U Hotstar Taq, 1Ã Hotstar Taq buffer, and 0.5 uM each primer, 5â²-ttttccctaagtttgtaagtagtgc-3; and 5â²-atccattttcttctctctgacc-3â². PCR consisted of 40 cycles of 95 degrees (1 min), 73 degrees (1 min), 57 degrees (45 sec), and 72 degrees (1 min).</p>
      </sec>
      <sec id="S6">
        <title>Plasmids</title>
        <p id="P15">A <italic>GNAQ<sup>Q209L</sup></italic> cDNA plasmid was obtained from UMR cDNA Resource Center. The wild-type counterpart was generated by site-specific mutagenesis. The coding regions of both constructs were epitope-tagged with an N-terminal Flag-tag and cloned into the lentiviral expression vector FG12. All constructs were sequenced for confirmation.</p>
      </sec>
      <sec id="S7">
        <title>Cell culture</title>
        <p id="P16">hTERT/CDK4<sup>R24C</sup>/p53<sup>DD</sup> melanocytes were cultured in glutamine containing Hamâs F12 supplemented with 7% FBS, 50 ng/ml TPA, 0.1 mM IBMX, 10 Î¼M Na<sub>3</sub>VO<sub>4</sub>, 1 mM dbcAMP. Primary normal melanocytes were cultured in MCDB153 supplemented 20% FBS, 2% chelated FBS, 5 Î¼g/ml L-glutamin, 15 Î¼g/ml cholera toxin, 0.5 ng/ml bFGF, 100 nM ET3 and 1.68 mM SCF. Cell lines OMM1.3, Mel202 and 293T were cultured in RPMI supplemented with 10% fetal bovine serum. Melan-a cells were cultured in glutamine-containing RPMI media supplemented with 10% FCS and 200 nM TPA.</p>
      </sec>
      <sec id="S8">
        <title>Lentiviral infection</title>
        <p id="P17">Viral supernatant were generated using 293T cells transfected with 10 Î¼g plasmid and appropriate lentiviral packaging plasmids. Media was changed 16 hr after transfection and the virus was harvested 40 to 56 hr later. hTERT/CDK4<sup>R24C</sup>/p53<sup>DD</sup>, melan-a and normal melanocytes were infected and infection efficiencies were estimated by the presence of GFP expressing cells.</p>
      </sec>
      <sec id="S9">
        <title>Transient transfection</title>
        <p id="P18">293T cells were seeded in 6-well plates at 1Ã10<sup>6</sup> cells per well with RPMI/10% FCS. Transfections were carried out using Lipofectamine 2000 (Invitrogen) and 2 Î¼g plasmid pcDNAâ¢6.2/V5-DESTÂ® Gateway vector (Invitrogen) alone or containing the complete coding region for either <italic>GNAQ<sup>Q209L</sup></italic> or <italic>GNAQ<sup>WT</sup></italic>, respectively. Cells were lysed 48 hour post-transfection and assayed for protein content.</p>
      </sec>
      <sec id="S10">
        <title>Tumorigenicity study</title>
        <p id="P19">Melan-a cells were lentiviral transfected with <italic>GNAQ<sup>WT</sup></italic>, <italic>GNAQ<sup>Q209L</sup></italic> and empty vector control. Seven days post infection, cells were resuspended in DMEM at 5 million cells per milliliter. Four month old, albino female nude mice (NU/J) were injected with 0.2 ml subcutaneously. Mice were palpated weekly.</p>
      </sec>
      <sec id="S11">
        <title>Cell proliferation assay</title>
        <p id="P20">Relative cell numbers were quantified by the CyQUANTÂ® Cell (Invitrogen) Proliferation Assay Kit according to the manufacturerâs protocol using 96-well plates. 7.5Ã10<sup>3</sup> cells were transfected and the fluorescent intensity was read after 72 hr.</p>
      </sec>
      <sec id="S12">
        <title>Immunofluorescence</title>
        <p id="P21">Human primary and hTERT/CDK4<sup>R24C</sup>/p53<sup>DD</sup> melanocytes were cultured on cover slips in 6 well plates and infected with lentiviral vectors containing either <italic>GNAQ<sup>Q209L </sup></italic><italic>GNAQ<sup>WT</sup></italic>, or an empty vector as control. Five days after infection, cells were fixed with 4% formaldehyde in PBS, permeabilized with 0.2 % Triton X100 and incubated with 3% BSA. Antibodies against pERK (E-4, Santa Cruz Biotechnology), cyclin D1 (M-20, Santa Cruz Biotechnology) and GNAQ (C-19, Santa Cruz biotechnology) were detected using secondary antibodies labeled with Alexa Fluor 594 and 532 (Molecular Probes). Images were taken at fixed exposures with an Axio Image M1 microscope (Zeiss, Germany). The fluorescence intensities were quantified using ImageJ software and the mean pixel intensities were used for statistical analysis using Microsoft Excel and Data Desk.</p>
      </sec>
      <sec id="S13">
        <title>Soft agar assay</title>
        <p id="P22">10Ã10<sup>3</sup> human primary melanocytes, hTERT/CDK4<sup>R24C</sup>/p53<sup>DD</sup> melanocytes stably expressing <italic>GNAQ<sup>Q209L</sup></italic>, <italic>GNAQ<sup>WT</sup></italic>, <italic>NRAS<sup>Q61R</sup></italic> or vector control and siRNA treated OMM1.3 and Mel202 cells were suspended in full media containing 0.35% agar and plated on a lower layer of 0.5% agar in 6 well plates. After 28 days, cells were stained with 0.005% crystal violet. Colony number and size were quantified using ImageJ software.</p>
      </sec>
      <sec id="S14">
        <title>Cell cycle analysis</title>
        <p id="P23">72 hr post transfection with siRNA against <italic>GNAQ</italic>, OMM1.3 and Mel202 cells were trypsinized, washed with cold PBS and fixed with 70% ethanol. Fixed cells were stained with propidium iodide. Cell cycle measurements were performed on a FACSCalibur (BD Biosciences), with minimum of 20,000 events, and profiles were analyzed using FlowJo and ModFit.</p>
      </sec>
      <sec id="S15">
        <title>siRNA transfection</title>
        <p id="P24">OMM1.3 and Mel202 were plated in RPMI/10% FCS in 6 well or 96 well plates at 1.5Ã10<sup>5</sup> or 5Ã10<sup>3</sup> cells per well, respectively. Two different pools; each comprised of four siRNA duplexes (pool 1: 5â²-CAAUAAGGCUCAUGCACAAUU-3â², 5â²-CGACGAGAAUAUCAAUUAUUU-3â², 5â²-GCAAGAGUACGUUUAUCAAUU-3â², 5â²-UAGUAGCGCUUAGUGAAUAUU-3â²; pool 2: 5â²-AUGCACAAUUAGUUCGAGAUU-3â², 5â²-UAUGAUAGACGACGAGAAUUU-3â², 5â²-CAGACAAUGAGAACCGAAUUU-3â², 5â²-CGCCACAGACACCGAGAAUUU-3â²) against <italic>GNAQ</italic> and ON-TARGETplus controls (all Dharmacon) were transfected in lipofectamine RNAiMax (1Î¼l/pmol siRNA) at 100 nM. siRNA complexes were formed in Optimem. Cells were lysed for <italic>analysis</italic> 72-96 hours post-transfection. For soft agar assay, 48 post transfection cells were used.</p>
      </sec>
      <sec id="S16">
        <title>Western blot analysis</title>
        <p id="P25">Cells were washed twice with ice-cold PBS and lysed in 50 mM TrisâHCl pH 7.8, 1% NP-40, 10% glycerol, 150 mM NaCl, 1 % Sodium deoxycholate, 1% sodium dodecyl sulfate, supplemented with protease inhibitor, phosphatase inhibitor and EDTA (Pierce Biotechnologies). The protein content of the lysates was determined by the BCA Protein Assay Reagent (Pierce Biotechnologies). 5-20 Î¼g of protein were separated by SDSâPAGE and transferred to Immobilon-P membrane (Millipore). Primary antibodies were: pERK (E-4, Santa Cruz Biotechnology), cyclin D1 (M-20, Santa Cruz Biotechnology) and GNAQ (C-19, Santa Cruz biotechnology), Cyclophilin B (Abcam), anti-FLAG M2 (Sigma), Anti-ERK Â½ pAb (Promega), and Î²-actin (Sigma). Secondary antibodies were labeled with horseradish peroxidase.</p>
      </sec>
      <sec id="S17">
        <title>Statistical analysis</title>
        <p id="P26">Immunofluorescence data and CyQUANT measurements were analyzed using Studentâs t-test. Fisherâs Exact test was used to compare the proportion of atypical cells.</p>
      </sec>
    </sec>
    <sec sec-type="supplementary-material" id="SM">
      <title>Supplementary Material</title>
      <supplementary-material content-type="local-data" id="SD1">
        <label>supplmentary data</label>
        <media xlink:href="NIHMS74666-supplement-supplmentary_data.pdf" mimetype="application" mime-subtype="pdf" xlink:type="simple" id="d37e817" position="anchor"/>
      </supplementary-material>
    </sec>
  </body>
  <back>
    <ack id="S18">
      <title>Acknowledgements</title>
      <p>We thank Dr. William Harbour, Washington University, Saint Louis, for providing additional DNA samples from uveal melanomas and Drs. Pablo Viciana-Rodriguez and Allan Balmain for providing advice. hTERT/CDK4<sup>R24C</sup>/p53<sup>DD</sup> melanocytes were a gift from Dr. David Fisher, Dana Farber Cancer Institute<xref rid="R13" ref-type="bibr">13</xref>, normal human melanocytes from foreskin were a gift from Dr. Meenhard Herlyn, The Wistar Institute, and OMM1.3 and Mel202 cells were originally from Dr. Bruce Ksander, Schepens Eye Research Institute. The melan-a cells were a gift from Dr. Dorothy Bennett, St Georgeâs University, London<xref rid="R23" ref-type="bibr">23</xref>.This work was supported by grants from the National Cancer Institute (P01 CA025874 Project 2 to BCB) the Melanoma Research Alliance, the Canadian Institutes of Health Research (MOP-79511 to CVR), and the National Institutes of Health (GSB).</p>
    </ack>
    <ref-list>
      <title>References</title>
      <ref id="R1">
        <label>1</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Davies</surname><given-names>H</given-names></name><etal/></person-group>
<article-title>Mutations of the BRAF gene in human cancer</article-title>
<source>Nature</source>
<year>2002</year>
<volume>417</volume>
<fpage>949</fpage>
<lpage>54</lpage>
<pub-id pub-id-type="pmid">12068308</pub-id></element-citation>
      </ref>
      <ref id="R2">
        <label>2</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pollock</surname><given-names>PM</given-names></name><etal/></person-group>
<article-title>High frequency of BRAF mutations in nevi</article-title>
<source>Nat Genet</source>
<year>2002</year>
<volume>25</volume>
<fpage>25</fpage>
</element-citation>
      </ref>
      <ref id="R3">
        <label>3</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Saldanha</surname><given-names>G</given-names></name><etal/></person-group>
<article-title>High BRAF mutation frequency does not characterize all melanocytic tumor types</article-title>
<source>Int J Cancer</source>
<year>2004</year>
<volume>111</volume>
<fpage>705</fpage>
<lpage>10</lpage>
<pub-id pub-id-type="pmid">15252839</pub-id></element-citation>
      </ref>
      <ref id="R4">
        <label>4</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Horsman</surname><given-names>DE</given-names></name><name><surname>White</surname><given-names>VA</given-names></name></person-group>
<article-title>Cytogenetic analysis of uveal melanoma. Consistent occurrence of monosomy 3 and trisomy 8q</article-title>
<source>Cancer</source>
<year>1993</year>
<volume>71</volume>
<fpage>811</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="pmid">8431862</pub-id></element-citation>
      </ref>
      <ref id="R5">
        <label>5</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Singh</surname><given-names>AD</given-names></name><name><surname>Bergman</surname><given-names>L</given-names></name><name><surname>Seregard</surname><given-names>S</given-names></name></person-group>
<article-title>Uveal melanoma: epidemiologic aspects</article-title>
<source>Ophthalmol Clin North Am</source>
<year>2005</year>
<volume>18</volume>
<fpage>75</fpage>
<lpage>84</lpage>
<comment>viii</comment>
<pub-id pub-id-type="pmid">15763193</pub-id></element-citation>
      </ref>
      <ref id="R6">
        <label>6</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zembowicz</surname><given-names>A</given-names></name><name><surname>Mihm</surname><given-names>MC</given-names></name></person-group>
<article-title>Dermal dendritic melanocytic proliferations: an update</article-title>
<source>Histopathology</source>
<year>2004</year>
<volume>45</volume>
<fpage>433</fpage>
<lpage>51</lpage>
<pub-id pub-id-type="pmid">15500647</pub-id></element-citation>
      </ref>
      <ref id="R7">
        <label>7</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Singh</surname><given-names>AD</given-names></name><etal/></person-group>
<article-title>Lifetime prevalence of uveal melanoma in white patients with oculo(dermal) melanocytosis</article-title>
<source>Ophthalmology</source>
<year>1998</year>
<volume>105</volume>
<fpage>195</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="pmid">9442799</pub-id></element-citation>
      </ref>
      <ref id="R8">
        <label>8</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Van Raamsdonk</surname><given-names>CD</given-names></name><name><surname>Fitch</surname><given-names>KR</given-names></name><name><surname>Fuchs</surname><given-names>H</given-names></name><name><surname>de Angelis</surname><given-names>MH</given-names></name><name><surname>Barsh</surname><given-names>GS</given-names></name></person-group>
<article-title>Effects of G-protein mutations on skin color</article-title>
<source>Nat Genet</source>
<year>2004</year>
<volume>36</volume>
<fpage>961</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="pmid">15322542</pub-id></element-citation>
      </ref>
      <ref id="R9">
        <label>9</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Markby</surname><given-names>DW</given-names></name><name><surname>Onrust</surname><given-names>R</given-names></name><name><surname>Bourne</surname><given-names>HR</given-names></name></person-group>
<article-title>Separate GTP binding and GTPase activating domains of a G alpha subunit</article-title>
<source>Science</source>
<year>1993</year>
<volume>262</volume>
<fpage>1895</fpage>
<lpage>901</lpage>
<pub-id pub-id-type="pmid">8266082</pub-id></element-citation>
      </ref>
      <ref id="R10">
        <label>10</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Landis</surname><given-names>CA</given-names></name><etal/></person-group>
<article-title>GTPase inhibiting mutations activate the alpha chain of Gs and stimulate adenylyl cyclase in human pituitary tumours</article-title>
<source>Nature</source>
<year>1989</year>
<volume>340</volume>
<fpage>692</fpage>
<lpage>6</lpage>
<pub-id pub-id-type="pmid">2549426</pub-id></element-citation>
      </ref>
      <ref id="R11">
        <label>11</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kalinec</surname><given-names>G</given-names></name><name><surname>Nazarali</surname><given-names>AJ</given-names></name><name><surname>Hermouet</surname><given-names>S</given-names></name><name><surname>Xu</surname><given-names>N</given-names></name><name><surname>Gutkind</surname><given-names>JS</given-names></name></person-group>
<article-title>Mutated alpha subunit of the Gq protein induces malignant transformation in NIH 3T3 cells</article-title>
<source>Mol Cell Biol</source>
<year>1992</year>
<volume>12</volume>
<fpage>4687</fpage>
<lpage>93</lpage>
<pub-id pub-id-type="pmid">1328859</pub-id></element-citation>
      </ref>
      <ref id="R12">
        <label>12</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lyons</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Two G protein oncogenes in human endocrine tumors</article-title>
<source>Science</source>
<year>1990</year>
<volume>249</volume>
<fpage>655</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="pmid">2116665</pub-id></element-citation>
      </ref>
      <ref id="R13">
        <label>13</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Garraway</surname><given-names>LA</given-names></name><etal/></person-group>
<article-title>Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma</article-title>
<source>Nature</source>
<year>2005</year>
<volume>436</volume>
<fpage>117</fpage>
<lpage>122</lpage>
<pub-id pub-id-type="pmid">16001072</pub-id></element-citation>
      </ref>
      <ref id="R14">
        <label>14</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hubbard</surname><given-names>KB</given-names></name><name><surname>Hepler</surname><given-names>JR</given-names></name></person-group>
<article-title>Cell signalling diversity of the Gqalpha family of heterotrimeric G proteins</article-title>
<source>Cell Signal</source>
<year>2006</year>
<volume>18</volume>
<fpage>135</fpage>
<lpage>50</lpage>
<pub-id pub-id-type="pmid">16182515</pub-id></element-citation>
      </ref>
      <ref id="R15">
        <label>15</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zuidervaart</surname><given-names>W</given-names></name><etal/></person-group>
<article-title>Activation of the MAPK pathway is a common event in uveal melanomas although it rarely occurs through mutation of BRAF or RAS</article-title>
<source>Br J Cancer</source>
<year>2005</year>
<volume>92</volume>
<fpage>2032</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="pmid">15928660</pub-id></element-citation>
      </ref>
      <ref id="R16">
        <label>16</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shin</surname><given-names>MK</given-names></name><name><surname>Levorse</surname><given-names>JM</given-names></name><name><surname>Ingram</surname><given-names>RS</given-names></name><name><surname>Tilghman</surname><given-names>SM</given-names></name></person-group>
<article-title>The temporal requirement for endothelin receptor-B signalling during neural crest development</article-title>
<source>Nature</source>
<year>1999</year>
<volume>402</volume>
<fpage>496</fpage>
<lpage>501</lpage>
<pub-id pub-id-type="pmid">10591209</pub-id></element-citation>
      </ref>
      <ref id="R17">
        <label>17</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dissanayake</surname><given-names>SK</given-names></name><etal/></person-group>
<article-title>The Wnt5A/protein kinase C pathway mediates motility in melanoma cells via the inhibition of metastasis suppressors and initiation of an epithelial to mesenchymal transition</article-title>
<source>J Biol Chem</source>
<year>2007</year>
<volume>282</volume>
<fpage>17259</fpage>
<lpage>71</lpage>
<pub-id pub-id-type="pmid">17426020</pub-id></element-citation>
      </ref>
      <ref id="R18">
        <label>18</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sheldahl</surname><given-names>LC</given-names></name><name><surname>Park</surname><given-names>M</given-names></name><name><surname>Malbon</surname><given-names>CC</given-names></name><name><surname>Moon</surname><given-names>RT</given-names></name></person-group>
<article-title>Protein kinase C is differentially stimulated by Wnt and Frizzled homologs in a G-protein-dependent manner</article-title>
<source>Curr Biol</source>
<year>1999</year>
<volume>9</volume>
<fpage>695</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="pmid">10395542</pub-id></element-citation>
      </ref>
      <ref id="R19">
        <label>19</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Marin</surname><given-names>YE</given-names></name><etal/></person-group>
<article-title>Stimulation of oncogenic metabotropic glutamate receptor 1 in melanoma cells activates ERK1/2 via PKCepsilon</article-title>
<source>Cell Signal</source>
<year>2006</year>
<volume>18</volume>
<fpage>1279</fpage>
<lpage>86</lpage>
<pub-id pub-id-type="pmid">16305822</pub-id></element-citation>
      </ref>
      <ref id="R20">
        <label>20</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mizushima</surname><given-names>J</given-names></name><name><surname>Nogita</surname><given-names>T</given-names></name><name><surname>Higaki</surname><given-names>Y</given-names></name><name><surname>Horikoshi</surname><given-names>T</given-names></name><name><surname>Kawashima</surname><given-names>M</given-names></name></person-group>
<article-title>Dormant melanocytes in the dermis: do dermal melanocytes of acquired dermal melanocytosis exist from birth?</article-title>
<source>Br J Dermatol</source>
<year>1998</year>
<volume>139</volume>
<fpage>349</fpage>
<lpage>50</lpage>
<pub-id pub-id-type="pmid">9767264</pub-id></element-citation>
      </ref>
      <ref id="R21">
        <label>21</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chang</surname><given-names>AE</given-names></name><name><surname>Karnell</surname><given-names>LH</given-names></name><name><surname>Menck</surname><given-names>HR</given-names></name></person-group>
<article-title>The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society</article-title>
<source>Cancer</source>
<year>1998</year>
<volume>83</volume>
<fpage>1664</fpage>
<lpage>78</lpage>
<pub-id pub-id-type="pmid">9781962</pub-id></element-citation>
      </ref>
      <ref id="R22">
        <label>22</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Curtin</surname><given-names>JA</given-names></name><etal/></person-group>
<article-title>Distinct sets of genetic alterations in melanoma</article-title>
<source>N Engl J Med</source>
<year>2005</year>
<volume>353</volume>
<fpage>2135</fpage>
<lpage>47</lpage>
<pub-id pub-id-type="pmid">16291983</pub-id></element-citation>
      </ref>
      <ref id="R23">
        <label>23</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bennett</surname><given-names>DC</given-names></name><name><surname>Cooper</surname><given-names>PJ</given-names></name><name><surname>Hart</surname><given-names>IR</given-names></name></person-group>
<article-title>A line of non-tumorigenic mouse melanocytes, syngeneic with the B16 melanoma and requiring a tumour promoter for growth</article-title>
<source>Int J Cancer</source>
<year>1987</year>
<volume>39</volume>
<fpage>414</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="pmid">3102392</pub-id></element-citation>
      </ref>
    </ref-list>
  </back>
  <floats-group>
    <fig id="F1" position="float">
      <label>Figure 1</label>
      <caption>
        <title><italic>GNAQ<sup>Q209L</sup></italic> transforms melanocytes</title>
        <p><bold>a</bold>, <italic>GNAQ<sup>Q209L</sup></italic> induces anchorage independent growth in soft agar of hTERT/CDK4<sup>R24C</sup>/p53<sup>DD</sup> melanocytes in a TPA-independent manner with comparable efficiency as NRAS<sup>Q61R</sup>. <bold>b,</bold> Cells expressing Flag-tagged GNAQ<sup>Q209L</sup> showed enlarged nuclei with irregular contours after 5 days. <bold>c,</bold> Melan-a cells<xref rid="R23" ref-type="bibr">23</xref> stably transduced with GNAQ<sup>Q209L</sup>, but not with wild-type GNAQ (n=3) or vector control (n=4), induce highly pigmented tumors of spindled and epithelioid melanocytes after 10 weeks in four out of five animals.</p>
      </caption>
      <graphic xlink:href="nihms-74666-f0001"/>
    </fig>
    <fig id="F2" position="float">
      <label>Figure 2</label>
      <caption>
        <title><italic>GNAQ<sup>Q209L</sup></italic> induces MAP kinase activation</title>
        <p><bold>a</bold>, Increased expression of pERK in hTERT/CDK4<sup>R24C</sup>/p53<sup>DD</sup> melanocytes transfected with <italic>GNAQ<sup>Q209L</sup></italic> compared to similar melanocytes transfected with <italic>GNAQ<sup>WT</sup></italic> or empty vector. <bold>b</bold>, Cumulative distribution of mean pixel fluorescence intensity per cell obtained from immunofluorescent detection of pERK (p-values: <italic>GNAQ<sup>Q209L</sup></italic> vs. vector). <bold>c</bold>, Western blot showing increased pERK levels in hTERT/CDK4<sup>R24C</sup>/p53<sup>DD</sup> melanocytes expressing Flag-tagged <italic>GNAQ<sup>Q209L</sup></italic> compared to cells transduced with Flag-tagged <italic>GNAQ<sup>WT</sup></italic> or vector control. <italic>NRAS<sup>Q61R</sup></italic> transduced melanocytes are shown as a positive control. * The band migrating just below the Flag band is non-specific reactive band in the lysate.</p>
      </caption>
      <graphic xlink:href="nihms-74666-f0002"/>
    </fig>
    <fig id="F3" position="float">
      <label>Figure 3</label>
      <caption>
        <title>Knockdown of GNAQ in OMM1.3 cells results in MAP-kinase inhibition, reduced growth and apoptosis</title>
        <p><bold>a</bold>, Western blot after treatment with 2 pools of siRNAs against <italic>GNAQ</italic> shows decreased pERK levels compared to control treated cells: cyclophilin B and non-target siRNA. <bold>b</bold>, After 72 hours, <italic>GNAQ</italic> knockdown results in marked reduction of cell numbers, similar to the effect of MEK inhibitor U0126. Bars show means and standard error of five replicate assays. * p&lt;0.05, t-test compared to mock or vehicle control, respectively. <bold>c</bold>, <italic>GNAQ</italic> knockdown reduces the number of colonies (upper left corner) formed in soft agar. <bold>d</bold>, Cell cycle profiles showing an increase of the sub-G0/G1 population after <italic>GNAQ</italic> knockdown.</p>
      </caption>
      <graphic xlink:href="nihms-74666-f0003"/>
    </fig>
    <table-wrap id="T1" position="float">
      <label>Table 1</label>
      <caption>
        <p>Frequency of <italic>GNAQ</italic> mutations in melanocytic neoplasms The number and type of samples analyzed is shown.</p>
      </caption>
      <table frame="hsides" rules="rows">
        <thead>
          <tr>
            <th align="left" valign="top" rowspan="1" colspan="1"/>
            <th align="left" valign="top" rowspan="1" colspan="1">Diagnosis</th>
            <th align="left" valign="top" rowspan="1" colspan="1">%<break/>Mutant</th>
            <th align="left" valign="top" rowspan="1" colspan="1">N</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">
<bold>Cutaneous and mucosal</bold>
<break/>
<bold>melanomas</bold>
</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Melanoma on skin without chronic sun-induced damage (non-<break/>CSD)<xref rid="R22" ref-type="bibr">22</xref></td>
            <td align="left" valign="top" rowspan="1" colspan="1">0%</td>
            <td align="left" valign="top" rowspan="1" colspan="1">15</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1"/>
            <td align="left" valign="top" rowspan="1" colspan="1">Melanoma on skin with chronic sun-induced damage (CSD)<xref rid="R22" ref-type="bibr">22</xref></td>
            <td align="left" valign="top" rowspan="1" colspan="1">4%</td>
            <td align="left" valign="top" rowspan="1" colspan="1">27</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1"/>
            <td align="left" valign="top" rowspan="1" colspan="1">Acral melanoma</td>
            <td align="left" valign="top" rowspan="1" colspan="1">0%</td>
            <td align="left" valign="top" rowspan="1" colspan="1">15</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1"/>
            <td align="left" valign="top" rowspan="1" colspan="1">Mucosal melanoma</td>
            <td align="left" valign="top" rowspan="1" colspan="1">0%</td>
            <td align="left" valign="top" rowspan="1" colspan="1">14</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1"/>
            <td align="left" valign="top" rowspan="1" colspan="1">âMalignant blue nevusâ</td>
            <td align="left" valign="top" rowspan="1" colspan="1">50%</td>
            <td align="left" valign="top" rowspan="1" colspan="1">2</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1"/>
            <td align="left" valign="top" rowspan="1" colspan="1">Melanoma arising in congenital nevus</td>
            <td align="left" valign="top" rowspan="1" colspan="1">0%</td>
            <td align="left" valign="top" rowspan="1" colspan="1">3</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1"/>
            <td align="left" valign="top" rowspan="1" colspan="1">Spitzoid melanoma</td>
            <td align="left" valign="top" rowspan="1" colspan="1">0%</td>
            <td align="left" valign="top" rowspan="1" colspan="1">2</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1"/>
            <td align="left" valign="top" rowspan="1" colspan="1">
<bold>Total</bold>
</td>
            <td align="left" valign="top" rowspan="1" colspan="1"/>
            <td align="left" valign="top" rowspan="1" colspan="1">
<bold>78</bold>
</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">
<bold>Nevi</bold>
</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Blue nevus</td>
            <td align="left" valign="top" rowspan="1" colspan="1">83%</td>
            <td align="left" valign="top" rowspan="1" colspan="1">29</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1"/>
            <td align="left" valign="top" rowspan="1" colspan="1">Nevus of Ota</td>
            <td align="left" valign="top" rowspan="1" colspan="1">6%</td>
            <td align="left" valign="top" rowspan="1" colspan="1">17</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1"/>
            <td align="left" valign="top" rowspan="1" colspan="1">Congenital nevus</td>
            <td align="left" valign="top" rowspan="1" colspan="1">0%</td>
            <td align="left" valign="top" rowspan="1" colspan="1">7</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1"/>
            <td align="left" valign="top" rowspan="1" colspan="1">Deep penetrating nevus</td>
            <td align="left" valign="top" rowspan="1" colspan="1">0%</td>
            <td align="left" valign="top" rowspan="1" colspan="1">16</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1"/>
            <td align="left" valign="top" rowspan="1" colspan="1">Proliferating nodule in giant congenital nevus</td>
            <td align="left" valign="top" rowspan="1" colspan="1">0%</td>
            <td align="left" valign="top" rowspan="1" colspan="1">7</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1"/>
            <td align="left" valign="top" rowspan="1" colspan="1">Spitz nevus</td>
            <td align="left" valign="top" rowspan="1" colspan="1">0%</td>
            <td align="left" valign="top" rowspan="1" colspan="1">8</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1"/>
            <td align="left" valign="top" rowspan="1" colspan="1">
<bold>Total</bold>
</td>
            <td align="left" valign="top" rowspan="1" colspan="1"/>
            <td align="left" valign="top" rowspan="1" colspan="1">
<bold>84</bold>
</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">
<bold>Ocular melanomas</bold>
</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Uveal melanoma</td>
            <td align="left" valign="top" rowspan="1" colspan="1">46%</td>
            <td align="left" valign="top" rowspan="1" colspan="1">48</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1"/>
            <td align="left" valign="top" rowspan="1" colspan="1">Uveal melanoma cell line</td>
            <td align="left" valign="top" rowspan="1" colspan="1">27%</td>
            <td align="left" valign="top" rowspan="1" colspan="1">15</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1"/>
            <td align="left" valign="top" rowspan="1" colspan="1">Conjunctival melanoma</td>
            <td align="left" valign="top" rowspan="1" colspan="1">0%</td>
            <td align="left" valign="top" rowspan="1" colspan="1">11</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1"/>
            <td align="left" valign="top" rowspan="1" colspan="1">
<bold>Total</bold>
</td>
            <td align="left" valign="top" rowspan="1" colspan="1"/>
            <td align="left" valign="top" rowspan="1" colspan="1">
<bold>74</bold>
</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1"/>
            <td align="left" valign="top" rowspan="1" colspan="1">
<bold>Grand Total</bold>
</td>
            <td align="left" valign="top" rowspan="1" colspan="1"/>
            <td align="left" valign="top" rowspan="1" colspan="1">
<bold>236</bold>
</td>
          </tr>
        </tbody>
      </table>
    </table-wrap>
  </floats-group>
</article>

</metadata></record></GetRecord></OAI-PMH>